Point72 Asset Management Reports New 5.7% Stake in Sutro Biopharma, Inc.

On May 1, 2026, Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen filed a Schedule 13G regarding their holdings in Sutro Biopharma, Inc. (STRO). The filing discloses a combined beneficial ownership of 946,829 shares of common stock, representing 5.7% of the company's outstanding shares. This position marks a significant increase from a previous 0.0% holding, crossing the 5% reporting threshold as of the event date on April 24, 2026. The shares are held directly by Point72 Associates, LLC, an investment fund managed by Point72 Asset Management. Steven A. Cohen controls both Point72 Asset Management and its general partner, Point72 Capital Advisors, Inc. The reporting persons share voting and dispositive power over the reported shares. Several sub-advisors, including Cubist Systematic Strategies, LLC and Point72 Asia (Singapore) Pte. Ltd., act under Point72 Asset Management's ADV. The filing includes a standard certification that the shares were acquired for investment purposes and not to influence control of the issuer.